Retina

Spotlight on the retina specialists who make up the Eye Care Network advisory boards

Businesses in the retina care space tease new technologies and cutting-edge therapeutics

As part of the Barcelona meeting, retina specialists can recognise the awareness day early

The contract research organization and technology solution is for the execution of ophthalmology clinical trials.

APP13007, according to the company, is the first product developed using Formosa’s proprietary APNT nanoparticle formulation platform.

Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.

The Retina Society meeting will take place in Lisbon, Portugal from September 11-15, 2024.

Identifying all genetic culprits may improve diagnostics and prognoses.

Focus on collaboration, career development and innovation

The Ramin Tadayoni Award supports the next generation of retina researchers while paying tribute to a leader in the field

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).

A team of researchers at the Center for Regenerative Therapies Dresden of Dresden University of Technology is working to develop a method to replace or regenerate damaged photoreceptor cells in the human retina.

This certification covers AI based regulatory requirements for the company's platform for AI imaging and diagnostic tools.

In this PER On Air Ophthalmology Times podcast, an expert panel discusses the latest advances in X-linked retinitis pigmentosa and how to optimize diagnosis as well as developments in gene therapy.

The future of the tech-forward surgical suite

Australian researchers have found that clinical registries may be an untapped font of information for artificial intelligence.

A meta-analysis indicates a "significant association" between vitamin D deficiency and increased risk of RVO

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilloedema

The product candidate is a modifier gene therapy for broad retinitis pigmentosa indication.

The option is a definitive step forward in the field of vitreoretinal surgery

According to the company, the priority review voucher would be issued upon approval of OPGx-LCA5.

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

Stephen R. Russell, MD, discussed the 9-year data he presented at the American Society of Retina Specialists annual meeting for voretigene neparvovec-rzyl.